Seasoned investor and operator with cross-border experience in growth-stage technology and healthcare companies. Malgorzata Serafin has led strategy, corporate development and M&A initiatives and worked with buyouts, minority growth investments and operational turnarounds. She brings a finance-oriented approach to portfolio value creation, board-level governance and exit planning, and typically engages with founders, PE sponsors and corporate acquirers.
Seasoned investor and operator with cross-border experience in growth-stage technology and healthcare companies. Malgorzata Serafin has led strategy, corporate development and M&A initiatives and worked with buyouts, minority growth investments and operational turnarounds. She brings a finance-oriented approach to portfolio value creation, board-level governance and exit planning, and typically engages with founders, PE sponsors and corporate acquirers.
Combines a finance-driven, operational lens to back growth-stage technology and healthcare companies across borders, prioritizing investments where strategic M&A, corporate development and governance can accelerate scale and exit value. Targets minority growth and control-oriented situations where board engagement, operational turnarounds and disciplined capital allocation unlock EBITDA improvement. Deploys medium-to-long horizon capital with rigorous due diligence, clear value-creation milestones and scenario-based risk sizing. Favors assets with strong founder alignment or sponsor partnerships, differentiated product-market fit and predictable regulatory pathways. Competitive edge lies in marrying dealcraft and execution—crafting integration plans, reinforcing commercial execution and shaping exit routes to capture multiple expansion.
Combines a finance-driven, operational lens to back growth-stage technology and healthcare companies across borders, prioritizing investments where strategic M&A, corporate development and governance can accelerate scale and exit value. Targets minority growth and control-oriented situations where board engagement, operational turnarounds and disciplined capital allocation unlock EBITDA improvement. Deploys medium-to-long horizon capital with rigorous due diligence, clear value-creation milestones and scenario-based risk sizing. Favors assets with strong founder alignment or sponsor partnerships, differentiated product-market fit and predictable regulatory pathways. Competitive edge lies in marrying dealcraft and execution—crafting integration plans, reinforcing commercial execution and shaping exit routes to capture multiple expansion.
| Trades 3355 | Longs Won 2090/3355 62% | Profit Factor 5 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $1.35M |
| Average Win $616,304.78 | Best Trade (Jun 02) $20.14M | Sharpe Ratio -7.12 |
| Average Loss -$203,710.44 | Worst Trade (Mar 31) -$6M | Z-Score -10.86 (100%) |
| Commissions $0 | Avg. Trade Length 1y 8m 1w 1d | Expectancy $307,118.71 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 6,757 | 6,081 | 5,405 | 4,730 | 4,054 | 3,378 | 2,703 | 2,027 | 1,351 | 676 |